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Abstract 
Prostaglandin D synthetase [PGD-S, prostaglandin-H 2 D-isomerase, (5Z, 13E)-(15S)-9a, 11 a-epidioxy-15-hydroxyprosta-5, 13-dien- 
oate D-isomerase, EC 5,3,99,2], an enzyme that catalyzes the formation of prostaglandin D 2, was originally isolated from homogenates of 
rat brain and spleen and is known to be a membrane-bound enzyme. Subsequent immunohistochemical studies have shown that PGD-S is 
associated with neurons in the brain of immature rats, whereas in adult rats it is associated with oligodendrocytes. Several recent studies 
have shown that the/3-trace protein isolated from human cerebrospinal fluid (CSF), the second most abundant protein in human CSF after 
albumin, is equivalent to PGD-S. In this paper, we report he preparation of a monospecific polyclonal antibody against purified PGD-S 
isolated from human CSF and the establishment of a specific radioimmunoassay for this protein. Using this radioimmunoassay in 
conjunction with immunoblot analysis, PGD-S was detected in various biological fluids including serum, aqueous humor, and rete testis 
fluid. In addition, an antibody prepared against human PGD-S partially cross-reacted with the PGD-S in the rat and ram. Using a 
monospecific polyclonal antibody prepared against purified rat PGD-S isolated from rat CSF in conjunction with [35S]methionine 
incorporation and immunoprecipitation techniques, it was shown for the first time that PGD-S is actively synthesized and secreted by 
astrocytes cultured in vitro, suggesting the astrocyte is the cellular origin of PGD-S in the CSF. The identification of the astrocyte as the 
cellular origin of this unique enzyme will allow the use of an in vitro system to study its regulation. 
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1. Introduction 
Prostaglandins are metabolites of arachidonic acid which 
have diverse biological fimctions in different mammalian 
tissues. Among these, prostaglandin D2 (PGD 2) is the 
major prostaglandin the. brain known to be involved in a 
variety of CNS functions including synaptic transmission 
[1], hypothalamic regulation of body temperature [2], in- 
duction of sleep [3-6], and the release of luteinizing 
hormone from the pituitaJry gland [7], as well as affecting 
other biological functions uch as smooth muscle contrac- 
tion and relaxation [8], vasoconstriction and/or vasodila- 
tion [9,10], growth and differentiation of rat glioma C6BU- 
1 cells [11], and depolarization of membrane potential of 
cultured neuroblastoma cells [ 12,13]. 
The formation of PGD 2 in humans is catalyzed by an 
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enzyme, prostaglandin D synthetase (PGD-S). PGD-S was 
originally isolated from rat spleen [14] and designated 
glutathione (GSH)-dependent PGD synthetase, whose en- 
zymatic reactivity is dependent on glutathione. Subse- 
quently, studies by other investigators have identified a 
brain-specific form of PGD-S, designated GSH-indepen- 
dent PGD-S, initially purified from rat brain homogenates 
[12,15], which is biochemically and immunologically dif- 
ferent from the GSH-dependent PGD synthetase isolated 
from the rat spleen [16]. The gene coding for the PGD-S 
has recently been mapped to chromosome 9, bands q32.2- 
q34.3 [17]. 
Other studies have shown that the brain-specific form of 
PGD-S is localized in the CNS [18], as well as other 
associated tissues such as the retina [19] and cochlea [20]. 
However, many of these earlier investigations suggested 
that PGD-S was a membrane-associated enzyme, since it 
was originally isolated from homogenates of either spleen 
[14] or brain [12,15]. Immunohistochemical localization of 
PGD-S revealed that it is present in the cochlear cells in 
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the cochlea of the ear [20], and neurons in the brain of 1- 
to 2-week-old rats whose localization was then shifted to 
the oligodendrocytes in adult animals [21]. Several recent 
reports, including two studies from this laboratory, have 
shown that PGD-S is a major CSF protein in the human, 
rat, and rabbit which is not a membrane-bound protein 
[22,23] and is equivalent to the /3-trace protein in the CSF 
[24,25]. 
In this report, we describe the preparation of a 
monospecific polyclonal antibody against human and rat 
PGD-S and the establishment of a specific radioimmunoas- 
say for the human PGD-S. We also demonstrate for the 
first time that rat astrocytes cultured in vitro actively 
synthesize and secrete PGD-S. 
2. Materials and methods 
Collection and preparation of biological fluids. Human 
CSF was collected from schizophrenic patients who under- 
went spinal taps and spinal myelograms. Rat and rabbit 
CSF was collected by cannulation of cisterna magna using 
a 22-gauge, 1.5-inch spinal needle attached to a 3-ml 
syringe from New Zealand White rabbits (2.5-3.0 kg body 
weight) and Sprague-Dawley rats (250-300 g body 
weight) immediately after the animals were killed by CO 2 
asphyxiation. About 0.5-1 ml and 0.05-0.1 ml of CSF 
was routinely obtained from rabbit and rat, respectively. 
Aqueous humor was also collected from these animals by 
inserting a 22-gauge hypodermic needle through the cornea 
immediately following their death. Monkey testicular cy- 
tosol, ram plasma, and ram rete testis fluid were collected 
as previously described [26]. All samples were centrifuged 
at 15 000 × g for 10 rain to remove cellular debris, and the 
clear supernatant was stored at -20°C until used. 
Purification of PGD-S by HPLC. Human and rat PGD-S 
was purified from the corresponding CSF as previously 
described [22,23], except that two sequential microbore 
HPLC were used, which included a Pharmacia gel perme- 
ation column (Superose 12, 3.2 × 300 mm, i.d.), and a 
Pharmacia C2/C 18 reverse-phase HPLC (/xRPC, 3.2 × 30 
mm, i.d.) following the Vydac C8 step. Briefly, fractions 
containing the PGD-S obtained from the Vydac C8 HPLC 
step were identified by SDS-PAGE and immunoblots [23]. 
They were pooled, lyophilized, and resuspended in 10 mM 
sodium phosphate, 0.15 M NaCI (pH 7.0) at 22°C contain- 
ing 20% ethanol (v/v).  This was then concentrated to 
about 100 /~1 using an Amicon Microcon-10 uitrafiltration 
unit, loaded onto the Superose 12 column and eluted using 
the above sodium phosphate buffer at a flow rate of 40 
/xl/min. The fractions containing the PGD-S were then 
pooled, concentrated to about 50 /~1 by ultrafiltration, 
diluted to 100 /xl with solvent A (5% acetonitrile/95% 
water, containing 0.1% trifluoroacetic acid, v /v )  and puri- 
fied to apparent homogeneity using a Pharmacia C2/C18 
microbore column with a linear gradient of 10-70% sol- 
vent B (95% acetonitrile/5% water, containing 0.1% tri- 
fluoroacetic acid, v /v )  over a period of 30 rain at a flow 
rate of 240 /zl/min. Fractions of 240 /zl each were 
collected, and the eluent was monitored by UV absorbance 
at 280 nm. The purity of the proteins was monitored by 
SDS-PAGE and silver staining. 
Preparation of anti-human PGD-S and anti-rat PGD-S 
antibody. The preparation of antibodies against purified 
human PGD-S and rat PGD-S isolated from the corre- 
sponding CSF was carried out as previously described in 
New Zealand White rabbits [26-28]. Briefly, about 70 /zg 
of purified protein suspended in 0.5 ml sterile water was 
emulsified with an equal volume of Freund's complete 
adjuvant and immunized at multiple sites in a rabbit 
subcutaneously. After 5-6 weeks, the rabbit received a 
first boost using 50 /zg of purified protein emulsified with 
Freund's incomplete adjuvant. About 1 week later, the 
rabbit received a second boost using the same amount of 
purified protein and Freund's incomplete adjuvant. Blood 
was removed from the rabbits 10 days after the second 
boost and every week thereafter. Blood was allowed to clot 
at 4°C overnight, centrifuged at 4000 × g for 20 rain and 
the antiserum was stored at -20°C until used. 
Calibration of anti-human PGD-S antiserum and 
radio-iodination of PGD-S for radioimmunoassay (RIA). 
To assess the working dilution of the antiserum to be used 
for RIA, serial dilutions of antiserum were prepared in the 
RIA buffer (10 mM sodium phosphate, 0.15 M NaC1, pH 
7.4 at 22°C, containing 0.5% BSA, w/v).  100 /xl of this 
antibody was then incubated with 0.3 ml of RIA buffer and 
100 /xl of the [JzsI]-labeled human PGD-S in a final 
reaction volume of 500 /~1. Radio-iodination of purified 
PGD-S was performed using [125I]Bolton Hunter reagent 
as previously described [27,29]. The reaction tubes were 
incubated at 4°C for 36 h. Thereafter, 30 /~1 of formalin- 
fixed Staphylococcus aureus cells [30] were added to each 
RIA tube and incubated for an additional hour at 4°C. The 
supernatant was then aspirated, and the radioactivity in the 
pellet was quantified by spectrometry using a Packard 
Cobra II y counter. A working dilution of 1:18 000 was 
selected, which gave a 25% binding of radioactivity at a 
final dilution of 1:90 000. 
Radioimmunoassay of PGD-S. For RIA, each assay 
tube contained 300 /zl of RIA buffer or unknown sample 
plus RIA buffer, 100/zl of antiserum at a working dilution 
of 1:18000, and 100 /xl of [125I]PGD-S (about 15000 
cpm) in a final reaction volume of 500 /zl. The mixture 
was vortexed briefly and incubated at 4°C for 36 h. 
Thereafter, 30 /xl of Staphylococcus aureus cells were 
added, incubated at 4°C for an additional hour, and the 
radioactivity in the pellet was determined as described 
above. All RIA data were computer analyzed by fitting 
standard curves to a four-parameter logistic function, and 
the unknowns were interpolated from the resultant curve 
using the computer program adapted from that of Rodbard 
et al. [31]. All unknowns were run in triplicate. Due to the 
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limited availability of the purified human PGD-S, the 
standard curve was calibrated using a pool of 1:100 diluted 
human CSF (SG-CSFSTD) at serial dilutions between 0.1 
and 300 /~1. When this laboratory standard was calibrated 
against a batch of highly purified human PGD-S, desig- 
nated SG-CSF001, 1 /zl of SG-CSFSTD (1:100 diluted 
using RIA buffer) contained 0.472 ng of PGD-S. The 
intra- and inter-assay coefficients of variation were 8 and 
12%, respectively. The minimal detectable dose was 0.26 
ng PGD-S/assay tube, and 50% displacement was at 14.5 
ng PGD-S. 
In vitro translation of human PGD-S. In vitro transla- 
tion of human PGD-S from the human brain poly(A)RNA 
was performed using a rabbit reticulocyte lysate system 
obtained from Promega (Madison, WI). Briefly, 0.5 /zg of 
human brain poly(A)RNA (Stratagene, La Jolla, CA), pre- 
viously heated at 68°C for 10 min and immediately chilled 
on ice, was incubated with 35 /xl nuclease-treated r ticu- 
locyte lysate, 1 /zl RNasin ribonuclease inhibitor (40 
units//xl), 1 /zl amino acid mixture (1 mM for each amino 
acid minus methionine), 100 ~Ci L-[35S]methionine (spec. 
act. 1200 Ci/mmol, NEN), and sterile water to a final 
reaction volume of 50 p,1. The reticulocyte translation 
reaction was incubated at 30°C for 60 min. Immunoprecip- 
itation of [35S]-labeled PGD-S was then performed as 
detailed elsewhere [28,32-34]. 
Primary cultures of rat astrocytes and immunoprecip- 
itation. Astrocytes were isolated from neonatal male pups 
1 day after birth as previously described from this labora- 
tory [32]. The purity of the cells was estimated by GFAP 
(glial fibrillary acidic protein) immunocytochemical st in- 
ing and was judged to be greater than 95%. The cells were 
then cultured under serum-free conditions as previously 
described [32]. To determine if astrocytes cultured in vitro 
indeed synthesize and secrete PGD-S, cells were plated at 
a density of 3 × 106 cells/dish/5 ml and maintained in a 
humidified atmosphere of 95% air/5% CO 2 at 37°C for 24 
h in serum-free FI2/DME medium (1/100th of the nor- 
mal methionine concentration) containing 100 /zCi of L- 
[35S]methionine. Medium was then collected, and the 
[35S]-labeled PGD-S was immunoprecipitated using the 
monospecific anti-rat PGD-S antibody as previously de- 
scribed from this laboratory [28,32-34]. 
General methods. Protein estimation was performed by 
Coomassie blue-dye binding assay [35]. Characterization 
of the monospecificity of the antibody was performed by 
crossed-immunoelectrophoresis in TTC buffer (0.32 M 
Tris, 0.2 M Tricine, and 1.5 mM calcium lactate [pH 8.6] 
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Fig. 1. Purification of PGD-S from human CSF and its structural analysis. (A) Purification of human PGD-S from CSF. Partially purified human PGD-S 
obtained from the sequential C8 reverse-phase and Superose TM 12 microbore (3.2 × 300 mm, i.d.) HPLC as described under Section 2 was purified to 
apparent homogeneity using a ~ILPC C2/C18 reversed-phase HPLC column (3.2 × 30 mm, i.d.). A total of four protein peaks were seen when the bound 
proteins were eluted using a linear gradient of 10-70% solvent B (95% ACN/5% water, containing 0.1% TFA) over a period of 30 min. Purified PGD-S 
was eluted under protein peak 2. (B) The purity of human PGD-S isolated from the C2/C18 HPLC column shown in Fig. 1A was assessed by SDS-PAGE 
on a 12.5% T SDS-polyacrylami,de gelunder educing conditions by silver staining. Lanes 1 and 2 correspond to the two fractions collected under protein 
peak 2 shown in Fig. 1A. The number on the left panel represents Bio-Rad protein molecular weight markers. (C) Peptide map of purified human PGD-S 
was generated using a Glu-C endopeptidase, Staphylococcus aureus protease V8 with a substrate:enzyme ratio of about 10:1 (5 Izg PGD-S:0.5 /zg 
enzyme) as described under Section 2 (lane 3). A total of 6 peptide fragments designated a- f  were visible following their separation by SDS-PAGE on a 
15% T SDS-polyacrylamide g l, electrophoretically transferred onto PVDF membrane, and stained with Coomassie brilliant blue R-250 [22,23]. The 
N-terminal amino acids of fragments e and f were determined by direct protein sequencing and described in the text. Lane 1 is Mr markers containing 
about 0.2 /zg protein each for BSA (Mr 68 000), ovalbumin (Mr 45 000), carbonic anhydrase (Mr 31000), soybean trypsin inhibitor (Mr 21500), and 
lysozyme (Mr 14400), and lane 2 is about 1.5 /zg protein of protease V8. 
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at 22°C containing 0.08% sodium azide, w/v)  and by 
immunoblots [26,34,36]. 
3. Results 
3.1. Purification of the soluble form of prostaglandin D
synthetase (PGD-S) from CSF 
PGD-S was purified to apparent homogeneity from 
human and rat CSF by sequential HPLC using C8, micro- 
bore gel permeation, and microbore C2/C18 reverse-phase 
columns. Fig. 1A shows the final HPLC purification step 
using a microbore C2/C18 column for the human PGD-S, 
where the highly purified protein was eluted under protein 
peak 2. The two fractions under this peak were resolved by 
SDS-PAGE, and the purified protein was visualized by 
silver staining (Fig. 1B). We routinely obtained about 120 
/zg of purified PGD-S from 10 ml of human CSF and 
about 140 /xg of purified PGD-S from 10 ml of rat CSF. 
Since earlier N-terminal amino acid sequence analyses 
revealed that PGD-S isolated from CSF displayed remark- 
able homology with the membrane bound PGD-S in the 
brain [37], we have performed a more detailed structural 
analysis of the PGD-S isolated from CSF to establish its 
identity. Fig. 1C shows the peptide fragmentation pattern 
of purified PGD-S (Fig. 1C, lane 3) using a GIu-C en- 
dopeptidase, Staphylococcus aureus protease V8 (Fig. 1C, 
lane 2). Among the 6 fragments, a-f, that were generated, 
fragments e (NH2-KKAALSMXKSVVAPAT) and f 
(NH2-TDYDQYALLYSQGSKGPG) that had been se- 
quenced yielded a sequence which corresponded to residues 
36-51 and residues 101-118 of the known human mem- 
brane bound PGD-S in the brain [37], respectively. These 
results thus confirm the studies of Zahn et al. [24] and 
Hoffmann et al. [25] and extend our earlier investigation 
[22,23] that PGD-S isolated from human CSF is indeed 
equivalent to the membrane bound PGD-S in the brain 
[37]. 
3.2. Distribution and the concentration of human PGD-S 
in various biological fluids 
Distribution of human PGD-S in biological fluids. Since 
it appears that PGD-S is present in a soluble form in the 
CSF, we next examined whether it is present in other 
biological fluids by immunoblots and RIA. Fig. 2A and 2B 
are the corresponding crossed-immunoelectrophoresis and 
immunoblot analyses using crude human CSF. These anal- 
yses revealed that the antibody prepared against purified 
human PGD-S was monospecific since only a single im- 
munoprecipitation arc (Fig. 2A) and a single immuno- 
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Fig. 2. Characterization f an anti-PGD-S antibody and the identification of immunoreactive PGD-S in biological fluids. (A) Crossed-immunoelectrophore- 
sis. About 10 /xl of crude human CSF containing about 3 /xg total protein was loaded onto the sample well (asterisk). It was then resolved onto a 1% 
agarose gel ( lst dimension). The agarose gel containing the CSF proteins was then removed and electrophoresis was performed on a 2nd dimension gel 
containing 3% anti-PGD-S antibody as described in Section 2. Only a single immunoprecipitation arcwas detected indicating the monospecificity of the 
antibody. (B) Immunoblot analysis of the antibody. About 10 /.*1 of crude human CSF containing about 3 /~g total protein was resolved by SDS-PAGE 
onto a 12.5% T SDS-polyacrylamide g l, transferred onto nitrocellulose paper and immunologically stained using a 1% anti-PGD-S antibody. (C). 
Identification of PGD-S in different biological fluids. Human CSF (lane 1 and 6 correspond to 30/zl  of fluid containing about 9 ~g total protein), human 
aqueous humor (lanes 2, 3 and 4 correspond to 20, 30, and 50/zl  fluid containing 5, 7.5 and 12.5/~g total protein, respectively), rat aqueous humor (lane 5 
corresponds to 50 /~1 fluid containing about 14 /zg total protein) and rat CSF (lane 7 corresponds to 50 /xl fluid containing 18 /~g total protein) were 
resolved onto a 12.5% T SDS-polyacrylamide g l, transferred onto nitrocellulose paper and immunologically stained with anti-human PGD-S antibody. S
denotes BRL prestained high M r markers. The immunoblot analysis was repeated twice using different batches of samples and similar results were 
obtained in each experiment. 
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reactive band corresponding to PGD-S (Fig. 2B) was 
noted. Fig. 2C shows that crude human CSF (Fig. 2C, 
lanes 1 and 6) contained the PGD-S, which is also present 
at a relatively high concentration i  human aqueous humor 
(Fig. 2C, lanes 2-4). Moreover, the anti-human PGD-S 
antibody also partially cross-reacted with the PGD-S in the 
rat CSF (Fig. 2C, lane 7) and rat aqueous humor (Fig. 2C, 
lane 5) which is in agreement with the competition curves 
generated using a human PGD-S RIA (Fig. 3). Both rat 
CSF and rat aqueous humor generated a partial displace- 
ment curve that competed with the binding of [~25I]-human 
PGD-S to its antibody only at high concentration (Fig. 
3C). This observation is apparently specific since rabbit 
CSF and aqueous humor at the same concentrations had no 
effect (Fig. 3C). In addition, these data are in agreement 
with the results of Urade el: al. [15] who had demonstrated 
an antibody prepared against rat brain PGD-S showed 
about 10% cross-reactivity with the human brain enzyme. 
In addition, these experiments were repeated three times 
using different batches of samples and similar results were 
obtained in each instance. 
Both crude human CSF and highly purified human 
PGD-S competed for the binding of the [~25I]PGD-S onto 
its antibody and yielded parallel and complete displace- 
ment curves (Fig. 3A), whereas rat serum, ram plasma 
(Fig. 3B), rabbit CSF, and rabbit aqueous humor had no 
apparent effect (Fig. 3C). However, monkey testicular 
cytosol, ram rete testis fluid, human serum, human aque- 
ous humor, rat CSF, and rat aqueous humor (Fig. 3B, C) 
also yielded parallel displacement curves, suggesting the 
presence of immunoreactive PGD-S in these fluids that 
shares epitopes with the human PGD-S. 
Level of human PGD-S in biological fluids. The con- 
centrations of PGD-S in different biological fluids and the 
corresponding total protein levels are shown in Table 1. It 
was found that the level ,of PGD-S is the highest in the 
CSF, followed by aqueous humor and the serum. The level 
of PGD-S in human CSF shown in Table 1 is consistent 
with the competition curves generated using two different 
human CSF samples hown in Fig. 3B,C. 
3.3. Identification of PGD-S in human brain by in vitro 
translation 
Using a rabbit reticulocyte cell-free translation system, 
the human poly(A)-RNA, and the anti-human PGD-S anti- 
body, a single immunoreactive band with an apparent M r 
of 23000, was identified by immunoprecipitation tech- 
niques (Fig. 4, lane 3) in the [35S]-labeled proteins follow- 
ing an in vitro translation reaction which was absent in the 
control, where immunoprecipitation was performed with 
preimmune serum (Fig. 4., lane 5 versus lane 3). It was 
noted that PGD-S was not readily visible in the total in 
vitro translation products in the presence (Fig. 4, lane 2) or 
absence (Fig. 4, lane 4) of human brain poly(A)-RNA (Fig. 
4, lanes 2, 4 versus lane 3). 
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Fig. 3. Displacement on the binding of [1251]human PGD-S onto its 
monospecific polyclonal anti-human PGD-S antibody by different biolog- 
ical fluids and proteins. (A) The displacement curves generated by a 
batch of purified human PGD-S (SG-CSF001) was compared to a pool of 
human CSF (SG-CSFSTD). The concentration of human PGD-S in 
SG-CSFSTD was 47.2 /xg/ml when titrated against a batch of purified 
human PGD-S, however, due to the limited supply of human CSF, this 
sample was diluted l:100 with RIA buffer prior to its use for RIA, thus 
its effective PGD-S concentration was 0.472 /zg/ml (see Section 2). The 
concentration of PGD-S in the purified sample (SG-CSF001) was 28.6 
/xg/ml when assayed by Bradford reagent [35]. Comparison of the 
displacement curves generated by human CSF and those using different 
biological fluids are shown in (B) and (C). RTF, rete testis fluid; TC, 
testicular cytosol. The protein concentration (mg/ml) in CSF, serum, 
plasma, monkey TC, RTF, and aqueous humor was about 0.3, 75, 80, 30, 
0.35, and 0.25, respectively. Only one set of data are shown here but each 
competition curve has been repeated three times using different batches 
of samples and identical results were obtained in each instance. Each data 
point is the mean of triplicate determinations. Standard eviation between 
triplicate assay tubes was 5-8% and is not shown due to the complexity 
of the graphs. 
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Fig. 4. In vitro cell-free translation of human PGD-S in a rabbit reticu- 
locyte system using human brain poly(A)-RNA and its visualization by 
immunoprecipitation using anti-human PGD-S antibody. This is a 12.5% 
T SDS-polyacrylamide g l running under reducing conditions. Lane 1 is 
[ 14 C]-labeled methylated protein markers from NEN consisting of myosin, 
M r 200000; phosphorylase b, M r 97000; BSA, M r 68000; ovalbumin, 
M, 45 000; carbonic anhydrase, M r 31000; soybean trypsin inhibitor, M~ 
21500; lysozyme, M r 14400. Lane 2 is the total [35S]-labeled proteins 
following in vitro translation of the human brain poly(A)-RNA in the 
reticulocyte system as described under Section 2. Lane 3 is the [35S]- 
labeled protein shown in lane 2 but immunoprecipitated with the anti-hu- 
man PGD-S antibody. Lanes 4 and 5 are the corresponding controls for 
lanes 2 and 3 where lane 4 is the [35S]-labeled proteins where the in vitro 
translation reaction was performed in the absence of human brain 
poly(A)-RNA. Lane 5 is identical to lane 3 except hat the [35S]-labeled 
proteins were immunoprecipitated with preimmune serum. The arrowhead 
indicates the specific translation product of PGD-S on lane 3 which has 
an apparent M r of 23000. The reduced apparent M r of this translation 
product compared to the PGD-S isolated from CSF is possibly the result 
of lack of glycosylation since PGD-S isolated from CSF was shown to be 
a Con A-reactive glycoprotein [23]. 
Table 1 
Concentration of PGD-S in different biological fluids from humans "
Human sample n PGD-S level Total protein level 
( /xg/ml)  (mg/ml)  
CSF 6 68+22 0.28+0.03 
Serum 5 10+2.5 70__+8 
Aqueous humor 3 25 ± 7 0.3 ! _+ 0.05 
* The level of PGD-S was quantified by RIA (see Section 2). Total 
protein content was quantified by Coomassie blue dye binding assay [35]. 
3.4. Synthesis and secretion of PGD-S by rat astrocytes 
To determine the cellular origin of the PGD-S in the 
CSF and to further confirm that this is indeed a secretory 
protein, we have examined whethe; astrocytes secrete this 
protein in vitro. Since human astrocytes were difficult to 
obtain, we had to perform this study using rat astrocytes 
isolated from neonatal rats 1 day after birth. Earlier studies 
from this laboratory have shown that rat CSF also con- 
tained PGD-S [22]. A monospecific polyclonal antibody 
was prepared using purified rat PGD-S isolated from CSF 
as previously described [22]. The identity of the purified 
rat PGD-S was confirmed by direct protein sequencing and 
was found to be NHz-HDTVQPNFQQDKFLG, which is 
identical to the rat brain PGD-S [37,38], except that the 
first eight amino acids, FPQTPAQG, from the N-terminus 
that were present in the rat brain PGD-S [37,38] could not 
be identified in the PGD-S isolated from the rat CSF. This 
observation has been confirmed using four different batches 
of highly purified PGE'-S from different pools of rat CSF. 
Both immunoblot analysis and crossed-immunoe- 
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Fig. 5. Synthesis and secretion of PGD-S by rat astrocytes cultured in vitro. Rat PGD-S was purified by sequential HPLC as described under Section 2. It 
was then used for the preparation of a monospecific antibody. (A) Characterization f the anti-rat PGD-S antibody by immunoblot. Lane 1 is BRL 
prestained molecular weight markers. Lanes 2 and 3 contained 30 /xl (about 9 /xg protein) and 10 /~1 (about 3 /.tg protein) of rat CSF, respectively; 
resolved by SDS-PAGE onto a 10% T SDS-polyacrylamide g l, transferred onto nitrocellulose paper and immunologically stained using the anti-rat 
PGD-S antibody. (B) Characterization f the anti-rat PGD-S antibody by crossed-immunoelectrophoresis. The experiment was performed as described in 
Section 2 and the legend to Fig. 2A except hat 10/zl of rat CSF (about 3 /zg protein) was used for the 1st dimension and a 3% anti-rat PGD-S antibody 
was used for the 2nd dimension. (C) Immunoprecipitation of [35S]-labeled rat PGD-S synthesized and secreted by astrocytes. The immunoprecipitated 
protein was extracted in SDS-sample buffer and resolved by SDS-PAGE on a 10% T SDS-polyacrylamide g l. Lane 1 is [14C]-labeled methylated protein 
markers. Lane 2 is the [35S]-labeled proteins secreted by astrocytes immunoprecipitated by the anti-rat PGD-S antibody. Lane 3 is the corresponding 
control using preimmune serum. 
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lectrophoresis confirmed the specificity of this antibody 
(Fig. 5A,B). When the [35S]-labeled products obtained 
from the spent medium of rat astrocytes cultured in vitro 
for 24 h with [3SS]methionine were immunoprecipitated 
with the anti-rat PGD-S antibody, a single immunoprecip- 
itated band with an apparent M r of 30000 was detected 
(Fig. 5, lane 2) which had the identical electrophoretical 
mobility of the purified rat PGD-S. This band was absent 
from the sample immunoprecipitated with the preimmune 
serum (Fig. 5, lane 3 versus lane 2). This study demon- 
strated PGD-S is indeed a secretary product of the astro- 
cytes. 
4. Discussion 
In this study, we have isolated a M r 30000 polypeptide 
from the CSF of both human and rat. Comparison of the 
partial N-terminal amino acid sequence of this protein 
isolated from CSF suggested that it is PGD-S [37], an 
enzyme that catalyzes the formation of prostaglandin D 2. 
Its identity was subsequently confirmed by direct protein 
sequencing of two of its internal peptide fragments. These 
results are consistent with two recent reports demonstrat- 
ing that PGD-S is a major CSF protein and is equivalent to 
the /3-trace protein [24,25], the second major CSF protein 
besides albumin [39], which was originally identified in 
CSF three decades ago. U,dng a polyclonal antibody pre- 
pared against purified human PGD-S, we have established 
a highly sensitive and specific radioimmunoassay for hu- 
man PGD-S. It is noted that the antibody prepared against 
the purified human PGD-S partially cross-reacted with the 
PGD-S in the rat and ram. IVlore important, we have shown 
that astrocytes cultured in vitro actively synthesize and 
secrete PGD-S, suggesting; that PGD-S identified in the 
CSF is not a metabolic breakdown product of the mem- 
brane-bound PGD-S, whic]h was thought o be associated 
with the membrane xtracts in the rat brain [37,38]. This 
result, however, cannot be used to argue that the PGD-S 
previously isolated from the brain and spleen extracts is 
not a membrane-bound enzyme. In view of the widespread 
presence of PGD-S in different biological fluids, it is 
possible that PGD-S is being synthesized by different cell 
types in the mammalian body. 
Using purified PGD-S isolated from the brain ho- 
mogenates of 4-week-old rats, it was shown that the 
N-terminus of the rat brain PGD-S contains eight extra 
amino acids NHz-FPQTPAQG [37,38], as compared to the 
rat CSF PGD-S. In four different batches of PGD-S iso- 
lated from the rat CSF, we unequivocally demonstrated a 
partial N-terminal amino acid sequence of NH2- 
HDTVQPNFQQDKFLG, which is identical to residues 
9-23 of the rat brain PGD-S [38]. The original rat brain 
PGD-S primary sequence was deduced from its nucleotide 
sequence analysis [38]. The immediate xplanation for 
such a discrepancy is not known, but it is possible that the 
first eight N-terminal amino acids of the original PGD-S 
sequence were part of the signal peptide. 
The physiological significance for the widespread pres- 
ence of PGD-S in different biological fluids is not known. 
Studies using radioimmunoassay have shown that the con- 
centration of PGD-S in the human CSF is several orders of 
magnitude higher than that of the serum in view of the 
high total protein content in the serum versus the CSF, 
suggesting PGD-S (the /3-trace protein) constitutes about 
15-25% of the total protein in CSF. These results are in 
agreement with previous observations since/3-trace protein 
is the second most abundant protein in human CSF after 
albumin [39]. Moreover, its concentration i the aqueous 
humor is also higher than that of the serum. However, its 
physiological function in these fluids is not clear. Prelimi- 
nary studies using highly purified PGD-S from the rabbit 
have shown that it can facilitate dopamine-mediated aortic 
contraction (data not shown) in an in vitro aortic bioassay 
[40,41]. Such an observation is not entirely unexpected 
since PGD 2 is known to be involved in smooth muscle 
contraction and relaxation, and vasoconstr ic-  
tion/vasodilation [8,9]. Since it has been shown that there 
is a developmental shift in the localization of PGD-S in the 
brain from neurons to oligodendrocytes [!6], it is believed 
that PGD-S may play a role in the growth of neuronal 
processes during development and may participate in 
myelin maintenance and its metabolism [16]. Other studies 
have shown that the addition of PGD 2 to neuroblastoma or 
hybridoma cells induces the growth of neurite-like struc- 
tures [42]. Thus, the presence of PGD-S in the CSF, 
aqueous humor, and rete testis fluid may suggest other 
unique roles of this enzyme in the CNS, eye, and testis. 
The demonstration f PGD-S as a secretory product of the 
astrocyte may provide new clues to study its regulation 
and function in the CNS. 
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